Liu Yu, Hong Zhenqiang, Chen Peng, Wang Jinzhao, Zhou Yimin, Huang Jianyun
Fujian University of Traditional Chinese Medicine, Key Laboratory of Orthopedics and Traumatology of Traditional Chinese Medicine and Rehabilitation, Ministry of Education, Fuzhou, Fujian 350122, P.R. China.
Department of Orthopedics, Third Affiliated Hospital of Fujian University of Traditional Chinese Medicine, Fuzhou, Fujian 350122, P.R. China.
Oncol Lett. 2019 Sep;18(3):3188-3194. doi: 10.3892/ol.2019.10617. Epub 2019 Jul 15.
Osteosarcoma (OS) is one of the most prevalent types of bone malignancies with poor overall prognosis, and is reported mainly in children and adolescents. Therefore, the investigation of novel and efficient treatment strategies for patients with OS is required. Baicalin exhibits potential anticancer effects, including in OS. However, its therapeutic effect against OS and the underlying mechanisms have not been fully evaluated. In the present study, the effect of baicalin on the proliferation and apoptosis of OS cells and its underlying mechanism of AKT pathway activation was explored. Cell confluence and cell number counts revealed suppressed the growth of OS cells that were treated with baicalin. Analysis of cell viability, cell survival and cell cycle, as well as cell apoptosis revealed decreased cell viability and survival, induced cell cycle arrest and apoptosis of treated cells. Western blot analysis demonstrated significantly decreased ratios of phosphorylated-AKT/AKT and Bcl-2/Bax, and decreased protein levels of cyclin D1 and CDK4 in cells treated with baicalin. Thus, the findings from the present study suggest that the suppression of the AKT pathway may be the underlying mechanism of the antitumor effect of baicalin in OS cells.
骨肉瘤（OS）是最常见的骨恶性肿瘤类型之一，总体预后较差，主要发生于儿童和青少年。因此，需要研究针对骨肉瘤患者的新型有效治疗策略。黄芩苷具有潜在的抗癌作用，包括对骨肉瘤。然而，其对骨肉瘤的治疗效果及潜在机制尚未得到充分评估。在本研究中，探讨了黄芩苷对骨肉瘤细胞增殖和凋亡的影响及其激活AKT通路的潜在机制。细胞汇合度和细胞计数显示黄芩苷处理可抑制骨肉瘤细胞的生长。细胞活力、细胞存活和细胞周期分析以及细胞凋亡分析显示，处理后的细胞活力和存活率降低，诱导细胞周期阻滞和凋亡。蛋白质印迹分析表明，黄芩苷处理的细胞中磷酸化-AKT/AKT和Bcl-2/Bax的比率显著降低，细胞周期蛋白D1和细胞周期蛋白依赖性激酶4的蛋白质水平降低。因此，本研究结果表明，抑制AKT通路可能是黄芩苷对骨肉瘤细胞抗肿瘤作用的潜在机制。
